Author’s response to reviews

Title: Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis

Authors:

Tao Xu (xutao@smmu.edu.cn)
Juxiang Chen (juxiangchen@126.com)
Yicheng Lu (luyc305@yahoo.cn)
Johannes E.A Wolff (jwolff@mdanderson.org)

Version: 7 Date: 27 May 2010

Author’s response to reviews:

Dear editor,

Thank you for your help about my paper! There is only one small changes in this revision.

In table 3 about the side effects, Zuniga cohort A and B shared the "Grade II-III hypertension (n=13), Grade I-II bleeding (n=9)", while the "Grade III proteinuria-renal failure (n=1), gastrointestinal perforation (n=1), severe nausea/vomiting (n=4)" only belongs to Zuniga cohort B. I have corrected it.

if there is any questions, please contact me.

Yours

Juxiang Chen